SITC Cancer Immunotherapy Guideline – Non-Small Cell Lung Cancer (NSCLC)

On July 17, 2018, the SITC Cancer Immunotherapy Guidelines Non-Small Cell Lung Cancer (NSCLC)
Expert Panel published a consensus statement specific to the treatment of patients with NSCLC.

This consensus statement consists of evidence-based recommendations from experts in the field for the use and sequencing of immunotherapies including nivolumab, pembrolizumab, atezolizumab and durvalumab. The statement also provides recommendations concerning patient selection, toxicity management and clinical endpoints.

SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of clinical practice guidelines developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced and will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

Current Guideline

UPDATE IN PROGRESS

view guideline

SITC Non-Small Cell Lung Cancer (NSCLC) Immunotherapy Guideline Expert Panel

Members

Charu Aggarwal, MD, MPH — University of Pennsylvania

Scott J. Antonia, MD, PhD — Duke University School of Medicine

Marianne Davies, DNP, AOCNP — Yale School of Nursing

Steven M. Dubinett, MD — David Geffen School of Medicine at UCLA

Andrea Ferris, MBA —  LUNGevity

Patrick Forde, MD — Johns Hopkins University School of Medicine

Edward B. Garon, MD — University of California, Los Angeles

Sarah B. Goldberg, MD, MPH — Yale School of Medicine, Yale Cancer Center

Matthew D. Hellmann, MD — Memorial Sloan Kettering Cancer Center

Fred R. Hirsch, MD, PhD — Icahn School of Medicine at Mount Sinai

Leora Horn, MD — Vanderbilt University Medical Center

Melissa L. Johnson, MD — Sarah Cannon Research Institute

Shakuntala Malik, MD — National Cancer Institute

Daniel Morgensztern, MD — Siteman Cancer Center, Washington University School of Medicine

Joel Neal, MD, PhD — Stanford University

Jyoti Patel, MD — Robert H. Lurie Comprehensive Cancer Center of Northwestern University

David L. Rimm, MD, PhD — Yale University

Sarah Sagorsky, PA-C — Johns Hopkins University School of Medicine

Lawrence H. Schwartz, MD — Columbia University Medical Center

Boris Sepesi, MD, FACS — The University of Texas MD Anderson Cancer Center